147 related articles for article (PubMed ID: 38326481)
21. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.
Scott EC; Hari P; Kumar S; Fraser R; Davila O; Shah N; Gale RP; Diaz MA; Agrawal V; Cornell RF; Ganguly S; Akpek G; Freytes C; Hashmi S; Malek E; Kamble RT; Lazarus H; Solh M; Usmani SZ; Kanate AS; Saad A; Chhabra S; Gergis U; Cerny J; Kyle RA; Lee C; Kindwall-Keller T; Assal A; Hildebrandt GC; Holmberg L; Maziarz RT; Nishihori T; Seo S; Kumar S; Mark T; D'Souza A
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2443-2449. PubMed ID: 30142419
[TBL] [Abstract][Full Text] [Related]
22. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.
Ozaki S; Handa H; Saitoh T; Murakami H; Itagaki M; Asaoku H; Suzuki K; Isoda A; Matsumoto M; Sawamura M; Sunami K; Takezako N; Hagiwara S; Kuroda Y; Chou T; Nagura E; Shimizu K
Ann Hematol; 2019 Jul; 98(7):1703-1711. PubMed ID: 31049648
[TBL] [Abstract][Full Text] [Related]
24. Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma.
Corso A; Galli M; Mangiacavalli S; Rossini F; Nozza A; Pascutto C; Montefusco V; Baldini L; Cafro AM; Crippa C; Cazzola M; Corradini P
Am J Hematol; 2012 Feb; 87(2):150-4. PubMed ID: 22189759
[TBL] [Abstract][Full Text] [Related]
25. Quantitative whole-body MR imaging for assessment of tumor burden in patients with multiple myeloma: correlation with prognostic biomarkers.
Sun M; Cheng J; Ren C; Zhang Y; Li Y; Li Y; Zhang S
Quant Imaging Med Surg; 2021 Aug; 11(8):3767-3780. PubMed ID: 34341748
[TBL] [Abstract][Full Text] [Related]
26. Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.
Du J; Lu J; Gao W; Liu J; He H; Li L; Li R; Zhou L; Jiang H; Chen W; Fu W; Hou J
Ann Hematol; 2020 Aug; 99(8):1779-1791. PubMed ID: 32594218
[TBL] [Abstract][Full Text] [Related]
27. Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM).
Zhong L; Hao P; Zhang Q; Jiang T; Li H; Xiao J; Li C; Luo L; Xie C; Hu J; Wang L; Liu Y; Shi Y; Zhang W; Gong B
Elife; 2022 Oct; 11():. PubMed ID: 36315425
[TBL] [Abstract][Full Text] [Related]
28. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
Galieni P; Travaglini F; Vagnoni D; Ruggieri M; Caraffa P; Bigazzi C; Falcioni S; Picardi P; Mazzotta S; Troiani E; Dalsass A; Mestichelli F; Angelini M; Camaioni E; Maravalle D; Angelini S; Pezzoni V
Br J Haematol; 2021 May; 193(3):542-550. PubMed ID: 33792026
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic value of the revised international staging system for newly diagnosed multiple myeloma patients].
Lu J; Du J; Fu WJ; He HY; Li L; Li R; Zhou LL; Jiang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):475-479. PubMed ID: 28655089
[No Abstract] [Full Text] [Related]
30. Baseline bone marrow ADC value of diffusion-weighted MRI: a potential independent predictor for progression and death in patients with newly diagnosed multiple myeloma.
Zhang L; Wang Q; Wu X; Zhao A; Feng J; Zhang H; Cao X; Li S; Cai H; Sun Z; Duan M; Zhu T; Zhang W; Jin Z; Zhou D; Xue H; Li J
Eur Radiol; 2021 Apr; 31(4):1843-1852. PubMed ID: 32965573
[TBL] [Abstract][Full Text] [Related]
31. The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis.
Chen H; Zhou N; Hu X; Wang D; Wei W; Peng R; Chen X; Shi H; Wu L; Yu W; Zhao W; Zhou F
Hematol Oncol; 2023 Feb; 41(1):139-146. PubMed ID: 36252280
[TBL] [Abstract][Full Text] [Related]
32. Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.
Song MK; Chung JS; Lee JJ; Lee JH; Song IC; Lee SM; Shin DY; Lee GW; Lee IS
Acta Haematol; 2015; 134(1):7-16. PubMed ID: 25832367
[TBL] [Abstract][Full Text] [Related]
33. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
[No Abstract] [Full Text] [Related]
34. Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation.
Çiftçiler R; Göker H; Demiroğlu H; Haznedaroğlu İC; Sayınalp N; Aksu S; Özcebe O; Büyükaşık Y
Turk J Haematol; 2021 Feb; 38(1):33-40. PubMed ID: 32539315
[TBL] [Abstract][Full Text] [Related]
35. [Validation of the prognostic value of the Mayo MASS and R2-ISS staging systems in patients newly diagnosed with multiple myeloma: A single-center study].
Xu Y; Shen XX; Jin YY; Li JY; Chen LJ; Zhang R
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):749-754. PubMed ID: 38049319
[No Abstract] [Full Text] [Related]
36. [Prognostic Value of A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma].
Wang Y; Yue LL; Zeng PY; Wu CY; Han Y; Song Y; Jin QQ; Jiang HY; Chai Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1779-1784. PubMed ID: 36476903
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation.
Mosebach J; Shah S; Delorme S; Hielscher T; Goldschmidt H; Schlemmer HP; Schönland S; Hegenbart U; Hillengass J
Haematologica; 2018 Feb; 103(2):336-343. PubMed ID: 29217779
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy and prognostic analysis of orthopedic surgery in patients with newly diagnosed multiple myeloma].
Zhang FJ; Zhou X; Liu SZ; Liu SJ; Liu Y; Zhuang JL
Zhonghua Nei Ke Za Zhi; 2023 Jun; 62(6):673-680. PubMed ID: 37263950
[No Abstract] [Full Text] [Related]
39. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.
Jakob C; Sterz J; Liebisch P; Mieth M; Rademacher J; Goerke A; Heider U; Fleissner C; Kaiser M; von Metzler I; Müller C; Sezer O
Leukemia; 2008 Sep; 22(9):1767-72. PubMed ID: 18580957
[TBL] [Abstract][Full Text] [Related]
40. Imaging findings and clinical features of patients with multiple myeloma with the prognostic effect of bone marrow focal and diffuse infiltration patterns on spine MRI.
Aribas BK; Arda K; Yologlu Z; Ciledag N; Aktas E; Ozdemir S; Dogan K; Fen T; Dagli M
Minerva Med; 2011 Apr; 102(2):115-24. PubMed ID: 21483398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
